Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Delcath inks FDA deal for design of Phase III trial

Delcath inks FDA deal for design of Phase III trial

By

Delcath

Delcath (NSDQ:DCTH) said yesterday the company reached a special protocol assessment agreement with the FDA for the design of a Phase III trial of its Delcath Hepatic Delivery System and Melphalan Hydrochloride.

The system is designed to treat patients with hepatic dominant ocular melanoma, the New York City-based company said. The company said the agreement acted as a stamp of approval for the trial, and if objectives in the trial are met, it would support the submission for regulatory approval with the FDA.

“This agreement marks a major milestone for Delcath. Under this SPA our new Focus trial, if successful, will provide a clear pathway to an indication in hepatic dominant ocular melanoma for Melphalan/HDS. Additionally, through the dedicated work of our team and in close collaboration with the FDA, we have satisfied a substantial number of the requirements of the FDA’s 2013 CRL. Based on our commercial experience in Europe, the continued support and enthusiasm from key opinion leaders and the clinical data that have been presented and published recently, we have confidence that our Focus trial can demonstrate the efficacy and safety necessary for a positive benefit/risk profile for Melphalan/HDS, and that the study’s objectives can be met. There is strong interest from leading cancer centers in the U.S. and Europe to participate in this study and we look forward to beginning enrollment in this registrational trial,” CEO Jennifer Simpson said in a press release.

The company said the agreement also satisfied a “substantial number of the FDA’s issues in the Complete Response Letter issued in September, 2013,” according to a press release. The issues mentioned were related to the safety of a previous generation of the drug device combo and procedure.

The company’s new Focus trial aims to evaluate the safety and efficacy of the drug device combo versus the best alternative care, with an endpoint of overall survival and secondary endpoints including progression-free survival, overall response rate and quality of life measures.

In case you missed it

RSS From Medical Design & Outsourcing

  • Automating manual processes for scalability
    Many medtech manufacturing processes are still performed manually for a variety of reasons. Assembling intricate products, such as an implantable cardiac device or wearable drug delivery device, requires a level of dexterity that, until recently, robots couldn’t deliver. Visual inspection is a critical part of quality control, but earlier machine vision technology couldn’t compete with… […]
  • Medtech AI developer Ketryx raises $14M in Series A round led by Lightspeed
    NEWS RELEASE: Ketryx raises $14M in Series A funding led by Lightspeed Venture Partners Investment fuels innovation to ensure patient safety and validate the use of AI in medical devices BOSTON, Mass, December 5, 2023: Ketryx, provider of the first and only connected application lifecycle management software for the life sciences industry, today announced that it… […]
  • TurboFil launches fully automatic TipFil syringe filling system
    NEWS RELEASE: TurboFil Introduces Fully Automatic Version of Popular Syringe Filling System TipFil™ Syringe Filling & Assembly Machine offers a fully automated start-to-finish process – from syringe loading, filling and capping through inspection, labeling and printing. Mount Vernon, NY – TurboFil Packaging Machines LLC, an equipment specialist dedicated solely to the design and development of… […]
  • Nissha Medical Technologies has a deal to buy Isometric Micro Molding
    Nissha Medical Technologies today announced a definitive agreement to acquire Isometric Micro Molding. Buffalo, New York–based Nissha Medical Technologies said it expects to close the deal by the end of 2023. Nissha Medical Technologies (a subsidiary of Kyoto, Japan-based Nissha Co.) is a contract development and manufacturing organization (CDMO) focused on minimally invasive surgical instruments… […]
  • BD limits executive severance after ‘golden parachute’ shareholder proposal overcomes board opposition
    Becton, Dickinson and Co. (BD) will now need stockholder permission for cash severance payouts to executives above a newly set limit. It’s the latest example of how executive compensation is being scrutinized in the medtech industry, where the world’s largest device manufacturers have collectively reduced headcount even as revenue hits record highs. BD’s medical and… […]
  • Study shows that electrodes implanted in the brain led to cognitive improvements
    A study published in Nature demonstrated that implanted electrodes could provide a potential therapy for chronic brain injuries. Led by Dr. Nicholas Schiff, the study looked at five people with moderate to severe brain injuries. They received electrode implants in the brain and, with stimulation from the electrodes, saw improvements in cognitive performance. Researchers told The New… […]
  • Millstone Medical Outsourcing plans testing services move to expanded facility
    NEWS RELEASE: Millstone Medical Outsourcing Will Move Testing Services to Expanded Facility in Bloomfield, CT Move expands facility footprint by 400% and includes new testing services Fall River, MA – Millstone Medical Outsourcing, the industry’s leading partner of choice for medical manufacturers’ post-manufacturing and aftermarket services, announces that it will move its testing services division… […]
  • Levita Magnetics hopes AI can take MARS robotic surgery platform to the next level
    After winning FDA clearance to add robotics to its first-of-its-kind magnetic surgery system, Levita Magnetics is looking to artificial intelligence as the next big step. Mountain View, California-based Levita Magnetics designed the MARS system for high-volume abdominal surgeries such as laparoscopic bariatric surgeries, cholecystectomies (gallbladder removal), and prostate and colorectal procedures. “Our MARS system [allows]… […]
  • How Medtronic evaluates its exposure to GLP-1 drugs
    Medtronic Chief Scientific, Medical and Regulatory Officer Dr. Laura Mauri drills into GLP-1 drug trial results to estimate their impact across the portfolio. The impact of glucagon-like peptide-1 (GLP-1) drugs like Ozempic and Wegovy on medtech manufacturing is one of the biggest uncertainties heading into 2024. Industry leaders like Medtronic, Stryker and Intuitive have faced… […]
  • Brain-computer interface lets ALS patient control home devices
    Researchers say they observed the successful translation of brain signals into computer commands with a brain-computer interface (BCI) implant. A team at Johns Hopkins surgically implanted the BCI on the brain of an ALS (amyotrophic lateral sclerosis) patient. They published their results, which showed the accurate translation of computer commands from brain activity, in Advanced Science.… […]
  • The 10 largest medtech employers of 2023 – and what their employees really think
    Employees at the 10 largest medtech employers in the world are finding a greater balance between work and life but are still frustrated by corporate bureaucracy. Those are just a few takeaways as Medical Design & Outsourcing compiled employees’ sentiments from reviews posted on Glassdoor. Total medtech jobs were down year-over-year in our 2023 Medtech… […]

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy